Literature DB >> 19628872

PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.

Vimal Selvaraj1, Mangala M Soundarapandian, Olga Chechneva, Ambrose J Williams, Maxim K Sidorov, Athena M Soulika, David E Pleasure, Wenbin Deng.   

Abstract

Poly(ADP-ribose) polymerase-1 (PARP-1) has been implicated in the pathogenesis of several central nervous system (CNS) disorders. However, the role of PARP-1 in autoimmune CNS injury remains poorly understood. Therefore, we studied experimental autoimmune encephalomyelitis (EAE), a model for multiple sclerosis in mice with a targeted deletion of PARP-1. We identified inherent physiological abnormalities in the circulating and splenic immune composition between PARP-1(-/-) and wild type (WT) mice. Upon EAE induction, PARP-1(-/-) mice had an earlier onset and developed a more severe EAE compared with WT cohorts. Splenic response was significantly higher in PARP-1(-/-) mice largely because of B cell expansion. Although formation of Th1 and Th17 effector T lymphocytes was unaffected, PARP-1(-/-) mice had significantly earlier CD4+ T lymphocyte and macrophage infiltration into the CNS during EAE. However, we did not detect significant differences in cytokine profiles between PARP-1(-/-) and WT spinal cords at the peak of EAE. Expression analysis of different PARP isozymes in EAE spinal cords showed that PARP-1 was down-regulated in WT mice and that PARP-3 but not PARP-2 was dramatically up-regulated in both PARP-1(-/-) and WT mice, suggesting that these PARP isozymes could have distinct roles in different CNS pathologies. Together, our results indicate that PARP-1 plays an important role in regulating the physiological immune composition and in immune modulation during EAE; our finding identifies a new aspect of immune regulation by PARPs in autoimmune CNS pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628872      PMCID: PMC2758007          DOI: 10.1074/jbc.M109.013474

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  79 in total

1.  PARP-2 deficiency affects the survival of CD4+CD8+ double-positive thymocytes.

Authors:  José Yélamos; Yolanda Monreal; Luis Saenz; Enrique Aguado; Valérie Schreiber; Rubén Mota; Teodomiro Fuente; Alfredo Minguela; Pascual Parrilla; Gilbert de Murcia; Elena Almarza; Pedro Aparicio; Josiane Ménissier-de Murcia
Journal:  EMBO J       Date:  2006-08-31       Impact factor: 11.598

2.  Intercellular adhesion molecule-1 expression is required on multiple cell types for the development of experimental autoimmune encephalomyelitis.

Authors:  Daniel C Bullard; Xianzhen Hu; Trenton R Schoeb; Robert G Collins; Arthur L Beaudet; Scott R Barnum
Journal:  J Immunol       Date:  2007-01-15       Impact factor: 5.422

3.  Active and passive experimental autoimmune encephalomyelitis in strain 129/J (H-2b) mice.

Authors:  R B Fritz; M L Zhao
Journal:  J Neurosci Res       Date:  1996-08-15       Impact factor: 4.164

4.  PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery.

Authors:  M Rouleau; D McDonald; P Gagné; M-E Ouellet; A Droit; J M Hunter; S Dutertre; C Prigent; M J Hendzel; G G Poirier
Journal:  J Cell Biochem       Date:  2007-02-01       Impact factor: 4.429

5.  Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.

Authors:  Z Q Wang; B Auer; L Stingl; H Berghammer; D Haidacher; M Schweiger; E F Wagner
Journal:  Genes Dev       Date:  1995-03-01       Impact factor: 11.361

6.  SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery.

Authors:  Matthew J Gamble; Robert P Fisher
Journal:  Nat Struct Mol Biol       Date:  2007-05-27       Impact factor: 15.369

7.  Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice.

Authors:  S D Wolf; B N Dittel; F Hardardottir; C A Janeway
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

8.  A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis.

Authors:  M Falcone; B R Bloom
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

Review 9.  Relationships among antigen presentation, cytokines, immune deviation, and autoimmune disease.

Authors:  F D Finkelman
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

10.  Loss of Parp-1 affects gene expression profile in a genome-wide manner in ES cells and liver cells.

Authors:  Hideki Ogino; Tadashige Nozaki; Akemi Gunji; Miho Maeda; Hiroshi Suzuki; Tsutomu Ohta; Yasufumi Murakami; Hitoshi Nakagama; Takashi Sugimura; Mitsuko Masutani
Journal:  BMC Genomics       Date:  2007-02-07       Impact factor: 3.969

View more
  17 in total

1.  Evaluation of the NAD+ biosynthetic pathway in ALS patients and effect of modulating NAD+ levels in hSOD1-linked ALS mouse models.

Authors:  Benjamin A Harlan; Kelby M Killoy; Mariana Pehar; Liping Liu; Johan Auwerx; Marcelo R Vargas
Journal:  Exp Neurol       Date:  2020-01-31       Impact factor: 5.330

2.  Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-kappaB-dependent signaling.

Authors:  Paola Castri; Yang-Ja Lee; Todd Ponzio; Dragan Maric; Maria Spatz; Joliet Bembry; John Hallenbeck
Journal:  Biochim Biophys Acta       Date:  2014-03

3.  Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord.

Authors:  Olga V Chechneva; Florian Mayrhofer; Daniel J Daugherty; David E Pleasure; Jau-Shyong Hong; Wenbin Deng
Journal:  Neurobiol Dis       Date:  2011-06-24       Impact factor: 5.996

Review 4.  Nicotinamide Adenine Dinucleotide Metabolism and Neurodegeneration.

Authors:  Mariana Pehar; Benjamin A Harlan; Kelby M Killoy; Marcelo R Vargas
Journal:  Antioxid Redox Signal       Date:  2017-06-27       Impact factor: 8.401

Review 5.  The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

Authors:  Raga Krishnakumar; W Lee Kraus
Journal:  Mol Cell       Date:  2010-07-09       Impact factor: 17.970

Review 6.  Beyond DNA repair, the immunological role of PARP-1 and its siblings.

Authors:  Maria Manuela Rosado; Elisabetta Bennici; Flavia Novelli; Claudio Pioli
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

Review 7.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

9.  PARP-1 regulates expression of TGF-β receptors in T cells.

Authors:  Pin Zhang; Hiroko Nakatsukasa; Eric Tu; Shimpei Kasagi; Kairong Cui; Masaki Ishikawa; Joanne E Konkel; Takashi Maruyama; Gang Wei; Brittany Abbatiello; Zhao-Qi Wang; Keji Zhao; WanJun Chen
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

10.  Modulation of PARP activity by Monomethylarsonous (MMA+3) acid and uranium in mouse thymus.

Authors:  Sebastian Medina; Xixi Zhou; Fredine T Lauer; Haikun Zhang; Ke Jian Liu; Johnnye Lewis; Scott W Burchiel
Journal:  Toxicol Appl Pharmacol       Date:  2020-12-03       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.